(Reuters) - GlaxoSmithKline's inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug.
Latest health news from http://reuters.us.feedsportal.com/c/35217/f/654207/s/49b10588/sc/14/l/0L0Sreuters0N0Carticle0C20A150C0A90C0A90Cus0Eglaxosmithkline0Etheravance0Ebreo0EidUSKCN0AR82GN20A150A90A90DfeedType0FRSS0GfeedName0FhealthNews/story01.htm
No comments:
Post a Comment